Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA issues warning on AAA (abdominal aortic aneurysms) endovascular graft devices

This article was originally published in Clinica

Executive Summary

The US FDA is warning physicians that serious problems, such as rupture and vessel damage, have occurred with the two endovascular graft devices now on the market for treatment of abdominal aortic aneurysms (AAA). The agency has not called for any change in how Guidant's Ancure System or Medtronic's AneuRx System are used. But its April 27 public health notification recommends that doctors make sure that all implanted patients are carefully followed and receive periodic follow-up imaging.

You may also be interested in...



Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel